# Ipamorelin Research: What Clinical Studies Show **By TelosRX Medical Team** · 2026-09-11 **Ipamorelin is a selective growth hormone-releasing peptide studied since the late 1990s for its ability to stimulate growth hormone secretion without significantly raising cortisol or prolactin. It is not FDA-approved and is available only through compounding pharmacies subject to provider evaluation and approval. Learn more at [TelosRX](https://telosrx.com).** Interest in growth hormone secretagogues (GHS) has grown alongside research into body composition, recovery, and healthy aging. Among the peptides studied in this class, ipamorelin has attracted attention for its selectivity — a property that distinguishes it from earlier GHS compounds and has shaped subsequent peptide research. ## Mechanism: How Ipamorelin Activates Growth Hormone Release Ipamorelin is a pentapeptide that binds selectively to the ghrelin receptor (growth hormone secretagogue receptor type 1a, or GHS-R1a) in the pituitary gland. Binding triggers pulsatile growth hormone (GH) release in a pattern that mimics natural physiological secretion. This pulsatile release is considered preferable to continuous GH elevation for maintaining receptor sensitivity. Unlike some earlier GHS compounds, ipamorelin’s receptor binding profile limits off-target stimulation of the hypothalamic-pituitary-adrenal axis. This selectivity became the subject of the peptide’s earliest clinical characterization. ## The Raun 1998 Selectivity Study: The Foundational Finding The pivotal early characterization of ipamorelin appeared in a 1998 paper by Raun et al. published in _European Journal of Endocrinology_ ([PMID 9849822](https://pubmed.ncbi.nlm.nih.gov/9849822/)). The study compared ipamorelin’s selectivity profile against GHRP-6, GHRP-2, and growth hormone-releasing hormone (GHRH) in rat models. Key findings included: - Ipamorelin produced GH release equivalent to GHRP-6 in potency but with substantially less cortisol and ACTH elevation - GHRP-2 and GHRP-6 both produced significant cortisol surges; ipamorelin did not at equivalent GH-releasing doses - Prolactin levels were not significantly elevated by ipamorelin, unlike the comparator peptides The authors concluded that ipamorelin represented “the first selective GHRP receptor agonist” — a characterization that defined how subsequent researchers categorized the compound. ## 2020 Review: Ipamorelin in the GHS Landscape A 2020 narrative review by Sigalos and Pastuszak published in _Urologic Clinics of North America_ examined growth hormone secretagogues in the context of male health, covering ipamorelin alongside sermorelin, MK-677, and CJC-1295 ([PMC7108996](https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/)). The review noted that ipamorelin’s selectivity for GH release over ACTH/cortisol stimulation was among the most favorable profiles in the secretagogue class. The authors identified the peptide as suitable for research into GH replacement approaches where HPA axis stimulation is undesirable — a common consideration in aging and chronic fatigue populations. Interested in how ipamorelin compares to a common combination protocol? See: [CJC-1295 + Ipamorelin: What the Research Shows on This Growth Hormone Stack](https://www.telosrx.com/blogs/peptides/cjc-1295-ipamorelin-growth-hormone-stack-research) ## Body Composition Research Preclinical studies by Lall and colleagues examined ipamorelin’s effects on adiposity in diet-induced obese animal models. Animals receiving ipamorelin showed reductions in fat mass and improvements in body composition metrics compared to controls, effects attributed to elevated GH pulsatility and downstream IGF-1 activity. Critically, these were animal studies. Controlled human trials examining ipamorelin’s body composition effects independently — separate from combination protocols — remain limited in number. Most human evidence comes from observational data and combination peptide protocols, which confounds isolated attribution to ipamorelin. ## GI Motility Research: Beck et al. An often-cited application of ipamorelin outside of body composition is gastrointestinal motility. A study by Beck and colleagues examined ipamorelin’s effects on postoperative ileus — delayed return of bowel function after abdominal surgery ([PMID 27186127](https://pubmed.ncbi.nlm.nih.gov/27186127/)). The investigators found that ipamorelin accelerated GI motility recovery in their model system. This work represented one of the few applications of ipamorelin to a clinical problem outside the GH axis, and it has been cited in subsequent discussions of GHS applications beyond body composition. ## Peptide Selectivity Comparison Peptide GH Release Cortisol/ACTH Effect Prolactin Effect Half-Life Ipamorelin Potent, pulsatile Minimal Minimal ~2 hours GHRP-6 Potent Moderate elevation Moderate elevation ~2 hours GHRP-2 Potent High elevation High elevation ~1 hour Sermorelin Moderate Minimal Minimal ~10 minutes CJC-1295 Prolonged Minimal Minimal ~8 days (DAC form) Data compiled from Raun 1998 (PMID 9849822) and Sigalos 2020 (PMC7108996). See also: [Sermorelin Research Guide: What Clinical Studies Show](https://www.telosrx.com/blogs/hormone-longevity/sermorelin-growth-hormone-peptide-research-guide) ## Safety Profile: What Studies Reported In the studies reviewed, ipamorelin’s side effect profile was limited. The most commonly noted effects were injection-site reactions (redness, mild discomfort) and transient flushing in some subjects. No significant cardiac, hepatic, or metabolic adverse events were reported in the preclinical and observational literature. Because ipamorelin is not FDA-approved and human trial data remain limited, long-term safety in humans is not established through controlled evidence. Use requires evaluation by a licensed provider. See also: [MK-677 (Ibutamoren): Growth Hormone Secretagogue Research](https://www.telosrx.com/blogs/peptides/mk-677-ibutamoren-growth-hormone-secretagogue) ## Frequently Asked Questions ### Is ipamorelin FDA-approved? No. Ipamorelin is not FDA-approved. It is available through compounding pharmacies subject to federal compounding regulations and requires evaluation and approval by a licensed provider. ### How does ipamorelin differ from sermorelin? Sermorelin mimics growth hormone-releasing hormone (GHRH) and acts at the GHRH receptor. Ipamorelin acts at the ghrelin receptor (GHS-R1a). They have different binding mechanisms and half-lives. Some protocols combine them; standalone research exists for each separately. ### What is the CJC-1295 + ipamorelin combination? CJC-1295 is a GHRH analog with a prolonged half-life. Combined with ipamorelin, the two peptides are thought to work synergistically — CJC-1295 extends GH release windows while ipamorelin provides pulsatile stimulation. Clinical evidence for the combination is limited and comes primarily from observational reports. ### What did the Raun 1998 study actually show? Raun et al. demonstrated that ipamorelin released growth hormone at potencies comparable to GHRP-6 while producing significantly less cortisol and ACTH elevation — characterizing it as the first selective GHRP receptor agonist. The study used rat models; human confirmation of the selectivity profile was noted in subsequent reviews. ### Can ipamorelin be used for GI motility issues? Ipamorelin has been studied in GI motility contexts, including postoperative ileus research (Beck et al., PMID 27186127). These are research findings, not clinical indications — any therapeutic application requires provider evaluation. ### Where can I learn about ipamorelin through a licensed telehealth provider? TelosRX offers asynchronous telehealth evaluation for peptide protocols. A licensed provider reviews your information and determines whether a protocol is appropriate. Approval is not guaranteed. Start your private evaluation at [TelosRX](https://telosrx.com). _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ **Tags:** body-composition, GHS, growth-hormone, ipamorelin, peptides, research, secretagogue --- > Source: [Telos RX](https://www.telosrx.com/blogs/peptides/ipamorelin-research-clinical-studies)